{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T08:52:23Z","timestamp":1792399943310,"version":"4.4.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,4,26]],"date-time":"2022-04-26T00:00:00Z","timestamp":1650931200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,4,26]],"date-time":"2022-04-26T00:00:00Z","timestamp":1650931200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetes Ther"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s13300-022-01262-8","type":"journal-article","created":{"date-parts":[[2022,4,26]],"date-time":"2022-04-26T10:03:32Z","timestamp":1650967412000},"page":"1161-1174","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy and Safety of LY2963016 Insulin Glargine in Chinese Patients with Type\u00a01 Diabetes Previously Treated with Insulin Glargine (Lantus\u00ae): a Post Hoc Analysis of a Randomized, Open-Label, Phase\u00a03 Trial"],"prefix":"10.1007","volume":"13","clinical-trial-number":[{"clinical-trial-number":"nct03338023","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Xiang","family":"Yan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiguang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,26]]},"reference":[{"issue":"Suppl 1","key":"1262_CR1","doi-asserted-by":"publisher","first-page":"S111","DOI":"10.2337\/dc21-S009","volume":"44","author":"American Diabetes Association","year":"2021","unstructured":"American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2021. Diabetes Care. 2021;44(Suppl 1):S111-s124.","journal-title":"Diabetes Care"},{"issue":"10138","key":"1262_CR2","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1016\/S0140-6736(18)31320-5","volume":"391","author":"LA DiMeglio","year":"2018","unstructured":"DiMeglio LA, Evans-Molina C, Oram RA. Type\u00a01 diabetes. Lancet. 2018;391(10138):2449\u201362.","journal-title":"Lancet"},{"key":"1262_CR3","unstructured":"Global Burden of Disease. Diabetes mellitus type\u00a01 \u2014 Level 4 cause. http:\/\/www.healthdata.org\/results\/gbd_summaries\/2019\/diabetes-mellitus-type-1-level-4-cause. Accessed Nov 2021."},{"issue":"5","key":"1262_CR4","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1159\/000355388","volume":"80","author":"C Gong","year":"2013","unstructured":"Gong C, Meng X, Saenger P, et al. Trends in the incidence of childhood type\u00a01 diabetes mellitus in Beijing based on hospitalization data from 1995 to 2010. Horm Res Paediatr. 2013;80(5):328\u201334.","journal-title":"Horm Res Paediatr"},{"issue":"2","key":"1262_CR5","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2021-002529","volume":"9","author":"Y Li","year":"2021","unstructured":"Li Y, Guo C, Cao Y. Secular incidence trends and effect of population aging on mortality due to type\u00a01 and type\u00a02 diabetes mellitus in China from 1990 to 2019: findings from the Global Burden of Disease Study 2019. BMJ Open Diabetes Res Care. 2021;9(2): e002529.","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"11","key":"1262_CR6","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.2337\/dc21-0342","volume":"44","author":"C Liu","year":"2021","unstructured":"Liu C, Yuan YC, Guo MN, et al. Incidence of type\u00a01 diabetes may be underestimated in the Chinese population: evidence from 21.7 million people between 2007 and 2017. Diabetes Care. 2021;44(11):2503\u20139.","journal-title":"Diabetes Care"},{"key":"1262_CR7","doi-asserted-by":"publisher","first-page":"j5295","DOI":"10.1136\/bmj.j5295","volume":"360","author":"J Weng","year":"2018","unstructured":"Weng J, Zhou Z, Guo L, et al. Incidence of type\u00a01 diabetes in China, 2010\u201313: population based study. BMJ. 2018;360:j5295.","journal-title":"BMJ"},{"issue":"7","key":"1262_CR8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0011501","volume":"5","author":"B Tao","year":"2010","unstructured":"Tao B, Pietropaolo M, Atkinson M, Schatz D, Taylor D. Estimating the cost of type\u00a01 diabetes in the U.S.: a propensity score matching method. PLoS ONE. 2010;5(7): e11501.","journal-title":"PLoS ONE"},{"key":"1262_CR9","doi-asserted-by":"publisher","first-page":"425","DOI":"10.2147\/DMSO.S87873","volume":"9","author":"F Wang","year":"2016","unstructured":"Wang F, Zassman S, Goldberg PA. rDNA insulin glargine U300\u2014a critical appraisal. Diabetes Metab Syndr Obes. 2016;9:425\u201341.","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"11","key":"1262_CR10","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.2337\/diacare.23.11.1666","volume":"23","author":"P Raskin","year":"2000","unstructured":"Raskin P, Klaff L, Bergenstal R, Hall\u00e9 JP, Donley D, Mecca T. A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type\u00a01 diabetes. Diabetes Care. 2000;23(11):1666\u201371.","journal-title":"Diabetes Care"},{"issue":"5","key":"1262_CR11","doi-asserted-by":"publisher","first-page":"639","DOI":"10.2337\/diacare.23.5.639","volume":"23","author":"RE Ratner","year":"2000","unstructured":"Ratner RE, Hirsch IB, Neifing JL, Garg SK, Mecca TE, Wilson CA. Less hypoglycemia with insulin glargine in intensive insulin therapy for type\u00a01 diabetes. U.S. Study Group of Insulin Glargine in Type\u00a01 Diabetes. Diabetes Care. 2000;23(5):639\u201343.","journal-title":"Diabetes Care"},{"issue":"3","key":"1262_CR12","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s40259-017-0218-5","volume":"31","author":"R Markus","year":"2017","unstructured":"Markus R, Liu J, Ramchandani M, Landa D, Born T, Kaur P. Developing the totality of evidence for biosimilars: regulatory considerations and building confidence for the healthcare community. BioDrugs. 2017;31(3):175\u201387.","journal-title":"BioDrugs"},{"issue":"10","key":"1262_CR13","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1111\/dme.13400","volume":"34","author":"M Davies","year":"2017","unstructured":"Davies M, Dahl D, Heise T, Kiljanski J, Mathieu C. Introduction of biosimilar insulins in Europe. Diabet Med. 2017;34(10):1340\u201353.","journal-title":"Diabet Med"},{"issue":"8","key":"1262_CR14","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1111\/dom.12496","volume":"17","author":"TC Blevins","year":"2015","unstructured":"Blevins TC, Dahl D, Rosenstock J, et al. Efficacy and safety of LY2963016 insulin glargine compared with insulin glargine (Lantus\u00ae) in patients with type\u00a01 diabetes in a randomized controlled trial: the ELEMENT 1 study. Diabetes Obes Metab. 2015;17(8):726\u201333.","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"1262_CR15","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s40259-018-0259-4","volume":"32","author":"YN Lamb","year":"2018","unstructured":"Lamb YN, Syed YY. LY2963016 insulin glargine: a review in type\u00a01 and 2 diabetes. BioDrugs. 2018;32(1):91\u20138.","journal-title":"BioDrugs"},{"issue":"8","key":"1262_CR16","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1111\/dom.12482","volume":"17","author":"J Rosenstock","year":"2015","unstructured":"Rosenstock J, Hollander P, Bhargava A, et al. Similar efficacy and safety of LY2963016 insulin glargine and insulin glargine (Lantus\u00ae) in patients with type\u00a02 diabetes who were insulin-na\u00efve or previously treated with insulin glargine: a randomized, double-blind controlled trial (the ELEMENT 2 study). Diabetes Obes Metab. 2015;17(8):734\u201341.","journal-title":"Diabetes Obes Metab"},{"key":"1262_CR17","unstructured":"European Medicines Agency. Abasaglar (previously Abasria). 2014. http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=\/pages\/medicines\/human\/medicines\/002835\/human_med_001790.jsp&mid=WC0b01ac058001d124. Accessed Dec 15, 2020."},{"key":"1262_CR18","unstructured":"US FDA approval of Basaglar (insulin glargine injection). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2015\/205692orig1s000toc.cfm. Accessed Sep 2021."},{"issue":"12","key":"1262_CR19","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1002\/cpdd.1014","volume":"10","author":"H Liu","year":"2021","unstructured":"Liu H, Wang F, Ji Y, et al. A euglycemic glucose clamp study to evaluate the bioavailability of LY2963016 relative to insulin glargine in healthy Chinese subjects. Clin Pharmacol Drug Dev. 2021;10(12):1452\u20139.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"12","key":"1262_CR20","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.2337\/dc14-2623","volume":"38","author":"H Linnebjerg","year":"2015","unstructured":"Linnebjerg H, Lam EC, Seger ME, et al. Comparison of the pharmacokinetics and pharmacodynamics of LY2963016 insulin glargine and EU- and US-approved versions of Lantus insulin glargine in healthy subjects: three randomized euglycemic clamp studies. Diabetes Care. 2015;38(12):2226\u201333.","journal-title":"Diabetes Care"},{"issue":"6","key":"1262_CR21","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1002\/cpdd.392","volume":"6","author":"X Zhang","year":"2017","unstructured":"Zhang X, Lam ECQ, Seger ME, et al. LY2963016 insulin glargine and insulin glargine (Lantus) produce comparable pharmacokinetics and pharmacodynamics at two dose levels. Clin Pharmacol Drug Dev. 2017;6(6):556\u201363.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"10","key":"1262_CR22","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.1111\/dom.14463","volume":"23","author":"X Yan","year":"2021","unstructured":"Yan X, Jiang S, Lou Y, Zhou Z. Comparable efficacy and safety between LY2963016 insulin glargine and insulin glargine (Lantus\u00ae) in Chinese patients with type\u00a01 diabetes: a phase\u00a0III, randomized, controlled trial. Diabetes Obes Metab. 2021;23(10):2226\u201333.","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"1262_CR23","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1111\/dom.14392","volume":"23","author":"W Feng","year":"2021","unstructured":"Feng W, Chen W, Jiang S, Du L, Zhu D. Efficacy and safety of LY2963016 insulin glargine versus insulin glargine (Lantus) in Chinese adults with type\u00a02 diabetes: a phase\u00a0III, randomized, open-label, controlled trial. Diabetes Obes Metab. 2021;23(8):1786\u201394.","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"1262_CR24","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s13300-018-0549-3","volume":"10","author":"RK Pollom","year":"2019","unstructured":"Pollom RK, Ilag LL, Lacaya LB, Morwick TM, Ortiz CR. Lilly insulin glargine versus Lantus\u00ae in insulin-na\u00efve and insulin-treated adults with type\u00a02 diabetes: a randomized, controlled trial (ELEMENT 5). Diabetes Ther. 2019;10(1):189\u2013203.","journal-title":"Diabetes Ther"},{"issue":"2","key":"1262_CR25","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1111\/dom.12584","volume":"18","author":"LL Ilag","year":"2016","unstructured":"Ilag LL, Deeg MA, Costigan T, et al. Evaluation of immunogenicity of LY2963016 insulin glargine compared with Lantus\u00ae insulin glargine in patients with type\u00a01 or type\u00a02 diabetes mellitus. Diabetes Obes Metab. 2016;18(2):159\u201368.","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"1262_CR26","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1111\/dom.12676","volume":"18","author":"HA Dowlat","year":"2016","unstructured":"Dowlat HA, Kuhlmann MK, Khatami H, Ampudia-Blasco FJ. Interchangeability among reference insulin analogues and their biosimilars: regulatory framework, study design and clinical implications. Diabetes Obes Metab. 2016;18(8):737\u201346.","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"1262_CR27","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1002\/cpt.1836","volume":"108","author":"L Barbier","year":"2020","unstructured":"Barbier L, Ebbers HC, Declerck P, Simoens S, Vulto AG, Huys I. The efficacy, safety, and immunogenicity of switching between reference biopharmaceuticals and biosimilars: a systematic review. Clin Pharmacol Ther. 2020;108(4):734\u201355.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"1262_CR28","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1177\/8755122518802268","volume":"35","author":"J White","year":"2019","unstructured":"White J, Goldman J. Biosimilar and follow-on insulin: the ins, outs, and interchangeability. J Pharm Technol. 2019;35(1):25\u201335.","journal-title":"J Pharm Technol"},{"key":"1262_CR29","unstructured":"US Food and Drug Administration. Immunogenicity testing of therapeutic protein products\u2014developing and validating assays for anti-drug antibody detection guidance for industry. https:\/\/www.fda.gov\/media\/119788\/download. Accessed Sep 2021."},{"issue":"1","key":"1262_CR30","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1208\/s12248-012-9408-8","volume":"15","author":"L Zhou","year":"2013","unstructured":"Zhou L, Hoofring SA, Wu Y, et al. Stratification of antibody-positive subjects by antibody level reveals an impact of immunogenicity on pharmacokinetics. AAPS J. 2013;15(1):30\u201340.","journal-title":"AAPS J"},{"issue":"4","key":"1262_CR31","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1111\/dom.12628","volume":"18","author":"I Hadjiyianni","year":"2016","unstructured":"Hadjiyianni I, Dahl D, Lacaya LB, Pollom RK, Chang CL, Ilag LL. Efficacy and safety of LY2963016 insulin glargine in patients with type\u00a01 and type\u00a02 diabetes previously treated with insulin glargine. Diabetes Obes Metab. 2016;18(4):425\u20139.","journal-title":"Diabetes Obes Metab"}],"container-title":["Diabetes Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-022-01262-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13300-022-01262-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-022-01262-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T21:09:08Z","timestamp":1654636148000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13300-022-01262-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,26]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["1262"],"URL":"https:\/\/doi.org\/10.1007\/s13300-022-01262-8","relation":{},"ISSN":["1869-6953","1869-6961"],"issn-type":[{"value":"1869-6953","type":"print"},{"value":"1869-6961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,26]]},"assertion":[{"value":"17 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}